Dcgi Approval News Today

Vaccine manufacturer Biological E. Limited today said that its COVID-19 vaccine Corbevax has received emergency use authorisation from the Drugs Controller General of India (DCGI) for the 5-12-year age group.

Pharma major Sun Pharmaceutical Industries Limited today said that one of its wholly owned subsidiaries has received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of MSD (a trade name of Merck & Co., USA) and Ridgeback’s molnupiravir under the brand name Molxvir in India for treatment of certain categories of adult patients with COVID-19.

URL copied Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine Drug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its COVID-19 vaccine ZyCoV-D. The company will now be initiating Phase III clinical trial in around 30,000 volunteers, Zydus Cadila said in a statement. ZyCoV-D was found to be safe, well-tolerated, and immunogenic in phase I and II clinical trials, it added. The phase II study of ZyC...

The vaccination schedule is likely to be announced by the Centre next week